For more on Immunovant’s new data, go here; for more on Sarepta’s gene therapy, go here; to learn more about Zealand’s deal with Roche, go here; and to read about the panels at our Breakthrough East ...

Eli Lilly & Co. (NYSE: LLY) shares are trading higher Thursday after the company launched its weight-loss drug Mounjaro in ...

The 2.5 mg vial and 5 mg vial will be available at Rs 3,500 and Rs 4,375, respectively. A spokesperson said as Mounjaro ...

Hollywood has in recent years been undergoing a much-needed, long-awaited transformation in its portrayals of women and ...

The U.S. Food and Drug Administration on Thursday launched an online searchable database listing contaminant levels in human ...

British investment firm SV Health Investors has secured $250 million to go toward the development of first-in-class ...

At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...

Eli Lilly’s Mounjaro has launched in India. Approved by CDSCO, it promises significant weight loss and blood sugar control. However, concerns remain over certain side effects.

The Danish drugmaker had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026. The active ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, outpacing competitor Novo Nordisk. With ...

Eli Lilly (NYSE:LLY) has launched its popular weight loss/diabetes therapy Mounjaro in India, beating its biggest rival, Novo ...